- Previous Close
6.99 - Open
7.04 - Bid 7.17 x 100
- Ask 7.24 x 300
- Day's Range
7.01 - 7.29 - 52 Week Range
6.30 - 30.60 - Volume
244,242 - Avg. Volume
526,885 - Market Cap (intraday)
310.658M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.12 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.75
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
kyvernatx.comRecent News: KYTX
View MorePerformance Overview: KYTX
Trailing total returns as of 9/13/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KYTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KYTX
View MoreValuation Measures
Market Cap
310.66M
Enterprise Value
-25.58M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.93
Enterprise Value/Revenue
3.34k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-75.92M
Diluted EPS (ttm)
-2.12
Balance Sheet and Cash Flow
Total Cash (mrq)
346.24M
Total Debt/Equity (mrq)
3.00%
Levered Free Cash Flow (ttm)
--
Research Analysis: KYTX
View MoreCompany Insights: KYTX
KYTX does not have Company Insights